Pfizer: An Environmental Threat To The Pharmaceutical Industry

According to the Center for Medicine and Medical Services the government pays 40% of all prescription drug costs putting additional stress on the federal budget. (Schueth).Currently the way Medicare Part D works is the more a customer has to pay the sooner they reach a more discounted benefit giving no incentive to seek cheaper generic brands or alternative medicines that are just as helpful. The effect of this for all is higher prescription drug costs and higher insurance costs. How this effects the retail pharmaceutical industry is either one extreme or the other. The more expensive the drug the more profit but the higher overall costs in general may reduce the buying power of baby boomers who no longer earn a regular paycheck.

The Bush Administration has acknowledged that there has been problems with implementation of the Medicare drug benefit but also contend that the benefit has helped most beneficiaries. On February 12, 2006, President Bush stated that competition between Medicare prescription drug plans has reduced costs for beneficiaries and taxpayers and that, on average, Medicare beneficiaries will pay about half of the amount that they paid for medications before the drug benefit was implemented. (American Health Line, Monday, February 13, 2006,

Yet they are only funded $2 billion a year. This sounds like a lot of money for one agency to have, but once you begin thinking of all the things the FDA is supposed to do, this amount is just not enough. The FDA is supposed to review every drug before it goes on the market. They are supposed to check and make sure that the drug does what it is supposed to and does not have any severe side effects, and that any side effect it does have is disclosed. Yet sometimes products go on the market with dangerous side effects, and it takes the FDA years to reveal it to the public.

Therefore the government should regulate the pharmaceutical industry because the industry is harmful towards the economy and patients. The government can achieve this by enabling a cap on prices of specialty drugs and ensuring DCTA is not

Pfizer has a significant amount of cash on hand and investments held overseas. Changes to the US corporate tax system now means overseas cash is taxed at 15%. This means Pfizer can more easily access funds with less penalty. Human Resources Management. • Staff Recruitment • Training

Problem Identification: Cialis was trying to enter into the market which was already well established by its competitors. The revenues of Pfizer were sky touching and they already had a mechanism to sell Viagra at very bottom level. They invested lot of money for branding Viagra using celebrities in TV commercials. Pfizer also had huge sales teams going to doctors and convince them to prescribe Pfizer’s medication to the patients.

According to Dr. Samadi, a board certified urologic oncologist, as Americans, we have spent more upon health care than any other developed nation, however we have the lowest life expectancy. The average life expectancy for an American is roughly 79 year old. When matched to other countries like Japan, Western Europe, and Great Britain their average life expectancy is 82 years old. In 2014, we spent 3.8 trillion dollars on health care. The main reason for this setback is that our diets contain a lot of processed foods, foods high in fats, sugars, sodium.

SOLVAY GROUP: INTERNATIONAL MOBILITY & MANAGING EXPATRIATES Group F2 Problem Statement: The situation is to develop an international mobility program in order to streamline processes at Solvay which aligns the company’s business goals with individual employees’ needs . External Analysis Factor (Economic, Technological, Cultural) Implications on the problem Political: • Swelling government regulations in Pharmaceutical industryIt was difficult to enter the industry(high entry barrier, not lucrative)Existing players diversifying globally Require additional HR • Movement of HR helps in easy expansion need of an effective international mobility program (take care employees needs like personal, financial, social etc.)

The FDA has a process in which they go about getting certain things off of the market to keep people safe; they first send out a warning to said companies and if the companies do not take into account

The consumers now demand for the products which are environmentally safe and having high packaging. Firms can be protect the natural environment demand by the public. In the United State about 20 million people are supporting environmental groups. The regulations from the federal and state governments are changing rapidly and becoming more complex. Most of the consumers, distributors, suppliers, and investors are closing business with environmentally weak firms.

The slogan, “We make everyday life better, every day,” comes from the worldwide manufacturer, Clorox, producing products such as cleaning supplies, pet supplies, and Burt’s Bees personal cosmetics. They are a multinational corporation with about 8,000 employees, and with a global net sales worth in excess of 5.66 billion dollars as of 2015, an increase compared to previous years. However, recent company research of the company shows that over the past two years, Clorox has had unfavorable foreign currency exchange rates, increased aggression in their competition, and a substantial increase rate in raw material costs. In this report, we will discuss the strengths, weaknesses, opportunities, and threats within all of their different brands consisting of cleaning supplies, pet supplies, and Burt’s Bees products. 2.0

According to "Wasteful Animal Testing", the US drug industry monopolize $50 billion per year in scientific researches, but the approval rate of these drugs has not changed in 50

After the side effects were discovered the FDA went back and researched the drug, and it was discovered that it causes defects across a wide range of species. Because of this catastrophe now it’s mandatory to do all the test before a product is

Many new companies to enter the market without burden of costly tasks such as research and development, clinical trials and manufacturing of drugs. Moreover, patent expiry is one of the reasons which is offering opportunities for lower cost generic manufacturer in terms of greater market access. Additionally, the government has increased their focus on healthcare cost cutting. It is creating pressure on the authority to allow early introduction of low-cost drugs in the

INTRODUCTION The latter decade of the 20th century brought a number of major innovations to the pharmaceutical industry, most notably a remarkable wave of successful joint ventures and mergers between big and medium players in the market. In this case study we analyzed the Rorer and Rhône-Poulenc (RP) merger in July 31, 1990 that created a major multinational company: the Rhône-Poulenc Rorer, Inc. (RPR), where the RP became the majority shareholder, owning 68 percent of the RPR’s shares. Prior to the merger, Rorer lacked the resources to access the European market, and the firm presented relatively low cash balance and rising debt which, according to financial analysts, appeared to be handicapping its strategy of growth by acquisitions.